Palvella Therapeutics (NASDAQ:PVLA) Stock: Insider George Jenkins Sells 7,174 Shares

Palvella Therapeutics, Inc. (NASDAQ:PVLA) Director George Jenkins sold 7,174 shares of the business’s stock in a transaction that occurred on Tuesday, October 13th. The stock was sold at an average price of $130.36, for a total value of $935,202.64. Following the transaction, the director owned 139,790 shares of the company’s stock, valued at approximately $18,223,024.40. This represents a 4.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Palvella Therapeutics Stock Performance

Shares of PVLA stock opened at $127.34 on Friday. Palvella Therapeutics, Inc. has a 1 year low of $68.96 and a 1 year high of $161.38. The firm has a market capitalization of $1.83 billion, a PE ratio of -26.36 and a beta of -0.27. The stock has a fifty day moving average of $146.19 and a two-hundred day moving average of $134.42.

Palvella Therapeutics (NASDAQ:PVLA) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($1.52) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.35). Equities research analysts predict that Palvella Therapeutics, Inc. will post -6.40 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

PVLA has been the topic of several research analyst reports. Canaccord Genuity Group set a $232.00 target price on shares of Palvella Therapeutics in a research note on Wednesday, August 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Palvella Therapeutics in a research report on Friday, September 25th. HC Wainwright reduced their price target on shares of Palvella Therapeutics from $270.00 to $246.00 and set a “buy” rating for the company in a research note on Monday. William Blair initiated coverage on shares of Palvella Therapeutics in a report on Friday. They issued an “outperform” rating for the company. Finally, Chardan Capital began coverage on shares of Palvella Therapeutics in a research note on Monday, September 21st. They set a “buy” rating and a $240.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $207.43.

Key Stories Impacting Palvella Therapeutics

Here are the key news stories impacting Palvella Therapeutics this week:

• Positive Sentiment: Palvella announced new pediatric analyses from its Phase 3 SELVA and Phase 2 TOIVA studies of investigational QTORIN™ rapamycin. The analyses showed improvements in disease severity and lesion characteristics in children with microcystic lymphatic malformations, as well as reduced lesion bleeding in children with cutaneous venous malformations. The treatment could potentially become the first FDA-approved therapy for both rare conditions, which currently have no approved treatments. Palvella pediatric clinical update
• Positive Sentiment: HC Wainwright maintained a Buy rating and a $246 price target, well above recent trading levels. The firm’s target suggests continued confidence in QTORIN’s commercial opportunity despite projected near-term losses.
• Neutral Sentiment: Palvella is presenting the SELVA and TOIVA results at the 2026 Pediatric Dermatology Research Alliance conference. While the data may improve visibility with physicians and investors, the company has not yet disclosed FDA approval, and the therapies remain investigational.
• Negative Sentiment: HC Wainwright reduced its EPS forecasts for 2027 through 2030, including estimates of losses of $13.52 per share in 2027, $10.40 in 2028 and $4.84 in 2029. Its 2030 profit forecast was cut to $5.82 from $19.10, implying a slower path to profitability and potentially greater funding needs.
• Negative Sentiment: Director George Jenkins sold 20,326 shares for approximately $2.69 million across October 12 and 13. The transactions were made under a pre-arranged Rule 10b5-1 plan, which reduces their significance as a current outlook signal, but the sizable insider selling may weigh on sentiment.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. BlackRock Inc. acquired a new stake in shares of Palvella Therapeutics during the 2nd quarter valued at $140,343,000. First Light Asset Management LLC grew its holdings in shares of Palvella Therapeutics by 38.3% in the 1st quarter. First Light Asset Management LLC now owns 980,758 shares of the company’s stock worth $122,251,000 after acquiring an additional 271,617 shares during the last quarter. Jennison Associates LLC grew its holdings in shares of Palvella Therapeutics by 65.3% in the 1st quarter. Jennison Associates LLC now owns 640,611 shares of the company’s stock worth $79,852,000 after acquiring an additional 253,128 shares during the last quarter. Summit Partners Public Asset Management LLC grew its holdings in shares of Palvella Therapeutics by 1,016.0% in the 4th quarter. Summit Partners Public Asset Management LLC now owns 389,420 shares of the company’s stock worth $40,761,000 after acquiring an additional 354,525 shares during the last quarter. Finally, Primecap Management Co. CA acquired a new stake in shares of Palvella Therapeutics during the second quarter worth $39,150,000. Institutional investors own 40.11% of the company’s stock.

About Palvella Therapeutics

Palvella Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for patients with rare and serious diseases. The company’s work centers on localized treatments intended to address conditions for which existing therapeutic options are limited.

Palvella’s lead investigational product is QTORIN 3.9%, a topical formulation of sirolimus designed to deliver the medicine directly to affected areas of the skin. The product is being developed for microcystic lymphatic malformations, rare vascular anomalies that can cause swelling, pain and disfigurement.